CBD Blocks Cancer Spread Pathway in Pancreatic Cancer Cells and 3D Tumor Models

CBD suppressed CXCR4/CXCR7 and MMP-2/9 expression, reducing migration and invasion in three pancreatic cancer cell lines. It reversed CXCL12-induced EMT by downregulating mesenchymal markers and restoring epithelial markers. CBD inhibited the long non-coding RNA MALAT1, and its overexpression reversed CBD effects. CBD plus gemcitabine showed synergistic inhibition of EMT and PI3K/Akt/mTOR signaling without additional cytotoxicity.

In vitro studies using MIA PaCa-2, PANC-1, and AsPC-1 pancreatic cancer cell lines. Assessed CBD effects on EMT markers, MALAT1 expression, PI3K/Akt/mTOR pathway, and invasion/migration. 3D spheroid models used for combination therapy with gemcitabine.

Pancreatic cancer has one of the worst prognoses of any cancer, largely because it metastasizes aggressively. If CBD can inhibit the EMT process that enables spread, it could complement existing chemotherapy, though this remains preclinical evidence.

The identification of MALAT1 as a specific molecular target of CBD in pancreatic cancer adds mechanistic depth to earlier observations of CBD anti-cancer properties. The synergy with gemcitabine without added toxicity is particularly relevant for a cancer with limited treatment options.

All work done in cell lines and 3D spheroids, not in animals or humans. CBD concentrations used in vitro may not be achievable in vivo. Pancreatic tumors in patients have complex microenvironments not captured by cell culture.